Regeneron, Sanofi Start Trials for Drug to Treat Covid-19
16 March 2020 - 11:57PM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceuticals Inc. and Sanofi said Monday they have
begun clinical trials to test a drug's efficacy in treating
patients with severe Covid-19 cases.
The Phase 2/3 trial, beginning at hospitals in New York, will
enroll as many as 400 patients to test the companies' sarilumab
drug in patients with severe disease caused by the new coronavirus.
The drug is an antibody that inhibits the interleukin-6 pathway,
which may have a part in lung inflammation in patients with the
disease, the companies said.
Preliminary results from a study in China showed that a similar
approach using a different drug were promising, the companies
said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
March 16, 2020 08:42 ET (12:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024